Xeris Biopharma Holdings, Inc.
XERS
$7.59
$0.020.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.84% | 47.94% | 35.39% | 12.31% | 26.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.84% | 47.94% | 35.39% | 12.31% | 26.46% |
| Cost of Revenue | 52.73% | 46.17% | 25.20% | 65.75% | 3.11% |
| Gross Profit | 48.08% | 48.24% | 37.48% | 1.39% | 32.25% |
| SG&A Expenses | 11.00% | 14.69% | -9.39% | 20.60% | 6.27% |
| Depreciation & Amortization | 0.04% | -0.04% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.21% | 15.17% | -3.52% | 26.16% | 4.20% |
| Operating Income | 154.75% | 78.31% | 179.05% | -162.43% | 48.76% |
| Income Before Tax | 86.48% | 50.62% | 62.48% | -52.17% | 30.52% |
| Income Tax Expenses | -- | -- | 100.00% | -883.43% | 210.96% |
| Earnings from Continuing Operations | 87.15% | 51.42% | 61.81% | -29.12% | 24.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 87.15% | 51.42% | 61.81% | -29.12% | 24.38% |
| EBIT | 154.75% | 78.31% | 179.05% | -162.43% | 48.76% |
| EBITDA | 244.69% | 99.42% | 259.24% | -445.28% | 59.67% |
| EPS Basic | 88.03% | 55.22% | 64.60% | -19.59% | 30.03% |
| Normalized Basic EPS | 87.86% | 56.10% | 105.75% | -69.85% | 35.40% |
| EPS Diluted | 88.03% | 55.22% | 64.60% | -19.59% | 30.03% |
| Normalized Diluted EPS | 87.86% | 56.10% | 105.75% | -69.85% | 35.40% |
| Average Basic Shares Outstanding | 7.49% | 8.49% | 7.94% | 7.92% | 8.01% |
| Average Diluted Shares Outstanding | 7.49% | 8.49% | 7.94% | 7.92% | 8.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |